Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
37 questions in 13 reviews · Hypertension
current versionsNo studies 37 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Evening vs morning dosing regimen Cardiovascular mortality (time points not specified) · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80… Evening versus morning dosing regimen drug therapy for hypertension (2024) · Cochrane | no estimate extracted | NR | No studies |
Evening vs morning dosing regimen Cardiovascular morbidity (stroke, myocardial infarction, congestive heart failure, aortic aneurysm) (time points not specified) · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80… Evening versus morning dosing regimen drug therapy for hypertension (2024) · Cochrane | no estimate extracted | NR | No studies |
First‐line thiazides vs first‐line ACE inhibitors Total serious adverse events · adults with hypertension First‐line diuretics versus other classes of antihypertensive drugs for hypertension (2023) · Cochrane | no estimate extracted | NR | No studies |
First‐line thiazides vs first‐line beta‐blockers Total serious adverse events · adults with hypertension First‐line diuretics versus other classes of antihypertensive drugs for hypertension (2023) · Cochrane | no estimate extracted | NR | No studies |
First‐line thiazides vs first‐line alpha‐blockers Total serious adverse events · adults with hypertension First‐line diuretics versus other classes of antihypertensive drugs for hypertension (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Pravastatin 10 to 80 mg/day (6 to 156 weeks) · participants with normal or abnormal lipid profiles Pravastatin for lowering lipids (2023) · Cochrane | no estimate extracted | NR | No studies |
Calcium supplementation/fortification vs control Adverse events (secondary outcome) · People who may be at risk for primary hypertension Calcium supplementation for prevention of primary hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Intensive periodontal treatment (subgingival SRP with or without other periodontal treatment) vs Supra-gingival scaling Proportion of participants diagnosed with hypertension at trial completion · Adults (any age/sex) with chronic periodontitis (>=5 teeth remaining; PPD >4 mm), with or without hypertension Effect of periodontal treatments on blood pressure (2021) · Cochrane | No included study in this comparison reported the proportion of participants diagnosed with hypertension at trial completion. | NR | No studies |
Intensive periodontal treatment (subgingival SRP with or without other periodontal treatment) vs Supra-gingival scaling Heart rate · Adults (any age/sex) with chronic periodontitis (>=5 teeth remaining; PPD >4 mm), with or without hypertension Effect of periodontal treatments on blood pressure (2021) · Cochrane | Heart rate was reported only by Higashi 2009 (periodontal treatment vs no treatment); no study in the intensive-treatment vs supra-gingival-scaling comparison reported heart rate. | NR | No studies |
Periodontal treatment (subgingival SRP with or without other periodontal treatment) vs No treatment (no periodontal treatment) Proportion of participants diagnosed with hypertension at trial completion · Adults (any age/sex) with chronic periodontitis (>=5 teeth remaining; PPD >4 mm), with or without hypertension Effect of periodontal treatments on blood pressure (2021) · Cochrane | No included study reported the proportion of participants diagnosed with hypertension at trial completion. | NR | No studies |
Roselle extract vs placebo Withdrawals due to adverse effects · hypertension in adults with type 2 diabetes mellitus Roselle for hypertension in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
Roselle extract vs placebo Change** in pulse pressure (mmHg) · hypertension in adults with type 2 diabetes mellitus Roselle for hypertension in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
Roselle extract vs placebo Change** in heart rate (beats/min) · hypertension in adults with type 2 diabetes mellitus Roselle for hypertension in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
Weight‐reducing diets vs no weight‐reducing diets Adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension Long‐term effects of weight‐reducing diets in people with hypertension (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Acronyms and grades · Male participants Effect of atorvastatin on testosterone levels (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Acronyms and grades · Adult female participants with PCOS Effect of atorvastatin on testosterone levels (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Cerivastatin dose · participants with normal or abnormal lipid profiles Cerivastatin for lowering lipids (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR CI: confidence interval · participants with normal or abnormal lipid profiles Cerivastatin for lowering lipids (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR aMean baseline values. · participants with normal or abnormal lipid profiles Cerivastatin for lowering lipids (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Cerivastatin dose · participants with normal or abnormal lipid profiles Cerivastatin for lowering lipids (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR CI: confidence interval · participants with normal or abnormal lipid profiles Cerivastatin for lowering lipids (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR aMean baseline values. · participants with normal or abnormal lipid profiles Cerivastatin for lowering lipids (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Cerivastatin dose · participants with normal or abnormal lipid profiles Cerivastatin for lowering lipids (2020) · Cochrane | no estimate extracted | NR | No studies |
Discontinuation by no treatment/placebo of antihypertensives vs continuation Falls ‐ not reported · Older adults, 50 years and older Withdrawal of antihypertensive drugs in older people (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR pitavastatin dose · participants with normal or abnormal lipid profiles Pitavastatin for lowering lipids (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR CI: Confidence interval · participants with normal or abnormal lipid profiles Pitavastatin for lowering lipids (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR aMean baseline values. · participants with normal or abnormal lipid profiles Pitavastatin for lowering lipids (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Pitavastatin dose · participants with normal or abnormal lipid profiles Pitavastatin for lowering lipids (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR CI: Confidence interval · participants with normal or abnormal lipid profiles Pitavastatin for lowering lipids (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR aMean baseline values. · participants with normal or abnormal lipid profiles Pitavastatin for lowering lipids (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR CI: Confidence interval · participants with normal or abnormal lipid profiles Pitavastatin for lowering lipids (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR aMean baseline values. · participants with normal or abnormal lipid profiles Pitavastatin for lowering lipids (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Pitavastatin dose · participants with normal or abnormal lipid profiles Pitavastatin for lowering lipids (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR CI: Confidence interval · participants with normal or abnormal lipid profiles Fluvastatin for lowering lipids (2018) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR CI: Confidence interval · participants with normal or abnormal lipid profiles Fluvastatin for lowering lipids (2018) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR CI: Confidence interval · participants with normal or abnormal lipid profiles Fluvastatin for lowering lipids (2018) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Angiotensin‐converting enzyme inhibitor · children (from 1 to 18 years of age) with hypertension from primary or secondary causes Pharmacological interventions for hypertension in children (2014) · Cochrane | no estimate extracted | NR | No studies |